N-Propionyl-Cysteaminylphenol-Magnetite Conjugate (NPrCAP/M) Is a Nanoparticle for the Targeted Growth Suppression of Melanoma Cells

Sato, Makito; Yamashita, Toshiharu; Ohkura, M.; Osai, Yasue; Satô, Akiko; Takada, Toru; Matsusaka, Hidenobu; Ono, Isao; Tamura, Yasuaki; Sato, Noriyuki; Sasaki, Yasushi; Ito, Akira; Honda, Hiroyuki; Wakamatsu, Kazumasa; Itô, Shôsuke; Jimbow, Kowichi

doi:10.1038/jid.2009.39

Cited by 41 publications

(37 citation statements)

References 25 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tumor-infiltrating T lymphocytes such as CD8 + and CD4 + T cells were observed both right and left tumors and tumorspecific cytotoxic T-lymphocyte (CTL) activity was augmented in the rats treated with MNHT. Jimbow et al also reported the anti-tumor immune responses induced by MNHT in mouse B16 melanoma models [22,23]. Thus, MNHT can kill not only heated tumors, but also non-heated tumors, including metastatic cancer cells.…”

Section: Induction Of Antitumor Immunity By Mnhtmentioning

confidence: 90%

“…The mice received daily intraperitoneal administration of NPrCAP/M. On the 15th day after injection of tumor cells, black brown MNPs were observed in B16F1 tumors whereas no substantial accumulation of the MNPs was observed in EG7 non-melanoma tumors [23].…”

Section: Magnetic Nanoparticles For Mnhtmentioning

confidence: 99%

“…A melanoma-targeted MNP was developed by directly conjugating a tyrosine homolog, N-propionyl-cysteaminylphenol (NPrCAP) that is a tyrosinase substrate, or indirectly doing NPrCAP with an end of the polyethylene glycol Antibody-conjugated magnetite 10 nm Targets to human breast cancer, conjugated with radioactive indium [25] Antibody-conjugated magnetoliposome 10 nm Targets to tumor cells, stabilizes the colloidal solution [26][27][28][29] Magnetoliposomes with encapsulated antitumor drug 20-30 nm Controlled drug release [31,32] MNPs in needle shape 10 nm Organs with high blood flow [33,34] chain on the surface of dextran-coated MNPs [22,23]. When the NPrCAPconjugated MNPs (NPrCAP/M) were added to cultures of various cell lines in vitro, no substantial uptake by non-melanoma cells was observed, whereas the MNPs uptake by melanoma cell lines was observed in higher percentage [23]. In an in vivo study, mouse B16F1 melanoma and EG7 lymphoma cells were injected into the left and right flank of mice, respectively.…”

Section: Magnetic Nanoparticles For Mnhtmentioning

confidence: 99%

See 2 more Smart Citations

Magnetic Nanoparticle-Mediated Hyperthermia and Induction of Anti-Tumor Immune Responses

Kobayashi

Ito

Honda

2016

Hyperthermic Oncology From Bench to Bedside

Self Cite

View full text Add to dashboard Cite

Magnetic nanoparticle-mediated hyperthermia (MNHT) can heat tumor tissue to the desired temperature without damaging surrounding normal tissue. The MNHT system consists of targeting tumor with functional magnetic nanoparticles (MNPs) and then applying an external alternating magnetic field (AMF) to generate heat in the MNPs. Temperature in the tumor tissue is increased to above 43 C, which causes necrosis of cancer cells but does not damage surrounding normal tissue. Among available MNPs, magnetite has been extensively studied. Recent years have seen remarkable advances in MNHT; both functional MNPs and AMF generators have been developed. By applying MNHT, heat shock proteins (HSPs) are highly expressed within and around tumor tissue, which causes intriguing biological responses such as tumor-specific immune response. These results suggest that MNHT is able to kill not only tumors exposed to heat treatment, but also unheated metastatic tumors at distant sites. Currently, some researchers have started clinical trials, suggesting that the time has come for clinical applications.

show abstract

Section: Induction Of Antitumor Immunity By Mnhtmentioning

confidence: 90%

Section: Magnetic Nanoparticles For Mnhtmentioning

confidence: 99%

Section: Magnetic Nanoparticles For Mnhtmentioning

confidence: 99%

See 1 more Smart Citation

Magnetic Nanoparticle-Mediated Hyperthermia and Induction of Anti-Tumor Immune Responses

Kobayashi

Ito

Honda

2016

Hyperthermic Oncology From Bench to Bedside

Self Cite

View full text Add to dashboard Cite

show abstract

“…95 Electron microscopy demonstrated this particle appeared only in melanoma cells. It was shown that the melanoma cells were degraded after the application of an external alternating magnetic field to increase the temperature in the tumor to 43°C.…”

Section: Magnetite Nanoparticlesmentioning

confidence: 99%

Applications of nanotechnology for melanoma treatment, diagnosis, and theranostics

Chen¹,

Shao²,

Zhang³

et al. 2013

IJN

View full text Add to dashboard Cite

Melanoma is the most aggressive type of skin cancer and has very high rates of mortality. An early stage melanoma can be surgically removed, with a survival rate of 99%. However, metastasized melanoma is difficult to cure. The 5-year survival rates for patients with metastasized melanoma are still below 20%. Metastasized melanoma is currently treated by chemotherapy, targeted therapy, immunotherapy and radiotherapy. The outcome of most of the current therapies is far from optimistic. Although melanoma patients with a mutation in the oncogene v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) have an initially higher positive response rate to targeted therapy, the majority develop acquired drug resistance after 6 months of the therapy. To increase treatment efficacy, early diagnosis, more potent pharmacological agents, and more effective delivery systems are urgently needed. Nanotechnology has been extensively studied for melanoma treatment and diagnosis, to decrease drug resistance, increase therapeutic efficacy, and reduce side effects. In this review, we summarize the recent progress on the development of various nanoparticles for melanoma treatment and diagnosis. Several common nanoparticles, including liposome, polymersomes, dendrimers, carbon-based nanoparticles, and human albumin, have been used to deliver chemotherapeutic agents, and small interfering ribonucleic acids (siRNAs) against signaling molecules have also been tested for the treatment of melanoma. Indeed, several nanoparticle-delivered drugs have been approved by the US Food and Drug Administration and are currently in clinical trials. The application of nanoparticles could produce side effects, which will need to be reduced so that nanoparticle-delivered drugs can be safely applied in the clinical setting.

show abstract

“…Thus, nanodrugs, once having entered the biological system, complexly interact with the host' s immune system, leading to premature clearance, side-effect activation, and toxicity (131)(132)(133)(134)(135). Consequently, the main limitations of nanodrug efficacy are the immunological interactions, the biological barriers that hinder the availability of nanodrugs to the intended target, and the heterogeneity of the biological target (38,136).…”

Section: Current Limitations and Exploring Possibilities For Improvinmentioning

confidence: 99%

Nanomedicine in Melanoma: Current Trends and Future Perspectives

El-Kenawy

Constantin

Hassan

et al. 2017

Cutaneous Melanoma: Etiology and Therapy

View full text Add to dashboard Cite

Abstract:As cutaneous melanoma is a highly aggressive and drug-resistant cancer, there is intense research focusing on developing new, efficient drugs. Nanomedicine focuses on developing different groups of nanomaterials for both diagnosis and therapy, and this combination of specific diagnosis and therapy is called theranostics. Nanomaterials tailored as delivery vehicles can be nanocapsules, nanorods, nanotubes, nanoshells, and nanocages. All these structures protect the intended drug against degradation and enhance its stability. The development and characterization of polymeric nanoparticles, polymeric micelles, liposomes, nanohydrogel, dendrimers, inorganic nanoparticles, and hybrid nanocarriers are among the delivery vehicles that transport different anticancer agents. Functionalization of nanocarriers with specific molecules, such as antibodies, can generate different smart nanodrugs for application in cancer therapy and/or diagnosis. Nanotherapeutic strategies deal with several shortcomings that comprise of tumor characteristics, biological barriers, biocompatibility, and so on. As nanostructures interact with various host biomolecules, comprehensive in vitro cellular models call for evaluation of physicochemical properties, dose, and time of action of nanomaterials, while in vivo assessments would provide valuable data regarding the level of absorption, tissue/organ distribution, and metabolism. The future perspectives in nanotechnology applied to cancer overcomes the translational barrier from the laboratory to the clinical application to potentially improve conventional theranostic techniques.

show abstract

N-Propionyl-Cysteaminylphenol-Magnetite Conjugate (NPrCAP/M) Is a Nanoparticle for the Targeted Growth Suppression of Melanoma Cells

Cited by 41 publications

References 25 publications

Magnetic Nanoparticle-Mediated Hyperthermia and Induction of Anti-Tumor Immune Responses

Magnetic Nanoparticle-Mediated Hyperthermia and Induction of Anti-Tumor Immune Responses

Applications of nanotechnology for melanoma treatment, diagnosis, and theranostics

Nanomedicine in Melanoma: Current Trends and Future Perspectives

Contact Info

Product

Resources

About